Recursion Notes Dr. Michael Secora Appointed CFO

CathWorks FFRangio™ System Receives National Reimbursement Approval in Japan

CathWorks announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the application to provide reimbursement for the CathWorks FFRangio™ System,...

Levine Leichtman Capital Partners Sells FlexXray

Levine Leichtman Capital Partners ("LLCP"), a Los Angeles-based private equity firm, announced today that it has sold its portfolio company FlexXray Holdings, LLC ("FlexXray" or...

Dr. Michael Secora will focus primarily on the Recursion’s fundraising and strategic finance events and will leverage his decade-plus of experience investing at the intersection of biology and technology.

“Decoding biology to radically improve lives is a bold ambition that requires substantial investment in a capital-intensive and revenue-deferred industry. We must be strategic in how we finance our company and achieve that ambition,” said Chris Gibson, Ph.D., Co-Founder and CEO, of Recursion. “Michael brings that forward-looking, strategic finance perspective to Recursion. He has evaluated and invested in approximately 900 IPOs mostly in biopharma and tech and knows what makes a company attractive to the markets. I am extraordinarily excited for how his expertise and innovative thinking will support our goal of continuing our buildout of the industry’s leading digital biology company.”

Before joining Recursion, Dr. Secora was Managing Director and Head of Capital Markets and Venture at Laurion Capital, an asset manager based in New York City who has been influential within the capital markets complex. He received his Ph.D. from Princeton University in Applied and Computational Mathematics and B.S. degrees from MIT in Mathematics and Physics. A self-proclaimed “student of the capital markets” with a scientific background, Michael has closely observed the emergence and evolution of technology-enabled drug discovery over the past few years, having worked with and invested in companies in that sector. However, Michael ultimately decided to join Recursion after spending 10 years at Laurion.

“I believe that we are at an important time in history where the advances in biotechnology in the next half-century may eclipse advances made in silicon and computational technology in the previous half-century. Moreover, I believe that this novel field of technology-enabled drug discovery has transformative potential for the cost and time to develop therapeutics as well as improving the quality of life for people suffering from disease,” said Dr. Secora. “To that end, I think that Recursion is best positioned to enact this vision and industrialize drug discovery. It is with passion that I accept the invitation to become Recursion’s CFO and bridge conventions in the fields of technology and biotechnology while innovating the means to capitalize.”

spot_img

DON'T MISS

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.